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 Zusammenfassung 
Zusammenfassung 
 
Chorea Acanthocytosis (ChAc) ist eine autosomal rezessive neurodegenerative Erkrankung 
mit Chorea, Dystonie, Epilepsie und Akanthozytose. Die Patienten haben eine verminderte 
Lebenserwartung von nur rund 60 Jahren. Die Störung wird durch eine 
Funktionsverlustmutation des VPS13A Gens (Vacuolar Protein Sortierung - assoziiertes 
Protein A) verursacht, welches das kodierende Gen für Chorein ist. Normalerweise stimuliert 
Chorein die Phosphoinositid-3-Kinase (PI3K), die an der Regulation des Ca2+ Einstrom 
beteiligt ist. Veränderungen der intrazellulären Ca2+-Konzentration regulieren unter anderem 
Proliferation, Differenzierung und Apoptose. Entleerung intrazellulärer Ca2+-Speicher 
aktiviert den Store-operated Ca2+ Entry (SOCE), der durch die Interaktion zwischen dem 
Ca2+-Sensorprotein, dem Stromal Interacting Molecule 1 (STIM1) und dem porenbildenden 
Orai1-Kanal zu einer Konformationsänderung und Öffnung des Kanals führt. Der Ca2+ Kanal 
wird auch Ca2+ release activated channel (CRAC) genannt. SOCE wird durch Lithium über 
Stimulation der Serum & Glukokortikoid-induzierbaren Kinase (SGK1) gesteigert. SGK1 ist 
in Zellen dafür verantwortlich, die Expression von Orai1 und STIM1 zu stimulieren und 
ebenfalls den Transkriptionsfaktor Nuclear factor 'kappa-light-chain-enhancer' von 
aktivierten B-Zellen (NFкB) zu regulieren. Lithium wird unter anderem zur Behandlung von 
bipolaren Erkrankungen eingesetzt und ist fähig die Bluthirnschranke zu passieren. In dieser 
Arbeit wurde gezeigt, dass Fibroblasten und Neurone von ChAc-Patienten einen 
verminderten SOCE und eine erhöhte Apoptoserate besitzen. Fibroblasten wurden von sechs 
ChAc-Patienten und sechs gesunden Spendern isoliert. Darüber hinaus wurden aus drei 
weiteren Patienten Fibroblasten entnommen und daraus induzierte pluripotente Stammzellen 
(iPSCs) erzeugt, um daraus Neurone zu differenzieren. Western Blotting und Calcium-
Imaging zeigten eine signifikante Verminderung der Orai1-Proteinmenge bzw. des SOCE in 
Fibroblasten und iPSC-basierten Neuronen von ChAc-Patienten im Vergleich zu gesunden 
Spendern. Die RT-PCR zeigte eine signifikante Verminderung der mRNA-Level von Orai1 
und STIM1 in iPSC-basierten Neuronen von ChAc-Patienten. Die Apoptose wurde durch 
Annexin-V/Propidiumjodid-Färbung mittels Durchflusszytometrie nachgewiesen und war bei 
Fibroblasten und iPSC-basierten Neuronen bei ChAc-Patienten signifikant höher als bei 
gesunden Spendern. 
In dieser Arbeit konnte gezeigt werden, dass die Behandlung der Fibroblasten und Neurone 
von ChAc-Patienten mit Lithium Calciumsignalwege positiv beeinflusst, während der Orai1-
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 Zusammenfassung 
Blocker, 2-Aminoethoxydiphenylborat (2-APB) den Effekt signifikant reduzierte. Lithium 
induzierte einen signifikanten Rückgang der Apoptose, der durch 2-APB aufgehoben wurde.  
Die mRNA- und Proteinexpression von Orai1 und STIM1 wurde durch Lithium erhöht, aber 
die Hemmung der SGK1 oder NFкB hat diesen Effekt umgekehrt.  
Zusammenfassend lässt sich sagen, dass die apoptotische Wirkung des Choreinmangels bei 
Fibroblasten und Neuronen von ChAc-Patienten zum Teil auf die verminderte Expression 
von Orai1, STIM1 und SOCE zurückzuführen war. Die Behandlung mit Lithium konnte 
diesen Effekt über den SGK1/NFкB Signalweg umkehren, weshalb Lithium eine neue 
Behandlung der ChAc darstellen könnte. 
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 Abstract 
Abstract 
 
Chorea Acanthocytosis (ChAc) is an autosomal recessive neurodegenerative disease 
characterized by limb chorea, dystonia, epilepsy and acanthocytosis. The patients have a 
reduced life expectancy of only around 60 years. This disorder is caused by a loss-of-function 
mutation of the VPS13A (vacuolar protein sorting-associated protein A) gene, which is the 
encoding gene of chorein. Normally, chorein stimulates phosphoinositide 3-kinase (PI3K), 
which is involved in the regulation of Ca2+ influx. Oscillations of intracellular Ca2+ 
concentration regulate, among other cell components, proliferation, differentiation and 
apoptosis. Emptying of intracellular Ca2+ stores activates the Store-operated Ca2+ entry 
(SOCE), which leads to a conformational change and opening of the channel through the 
interaction between the Ca2+ concentration sensor protein, the Stromal Interacting Molecule 1 
(STIM1), and the pore-forming channel, Orai1. The Ca2+ channel is known also as Ca2+ 
release-activated channel (CRAC). 
SOCE is increased by lithium via stimulation of serum & glucocorticoid-inducible kinase 
(SGK1), which is responsible in cells for stimulating the expression of Orai1 and STIM1 as 
well regulating the transcription factor: Nuclear Factor 'kappa-light-chain-enhancer' of 
activated B-cells (NFкB). Lithium is used in the treatment of bipolar disorders and can cross 
the blood-brain barrier (BBB). 
In this study, fibroblasts and neurons of ChAc patients have been shown to have decreased 
SOCE and an increased rate of apoptosis. Fibroblasts were isolated from six ChAc patients 
and six healthy donors. In addition, fibroblasts were obtained from three additional patients 
and healthy donors and induced pluripotent stem cells (iPSCs) were generated in order to 
differentiate them into neurons. Western blotting and calcium imaging showed a significant 
reduction in the amount of Orai1 protein and SOCE, respectively, in fibroblasts and iPSC-
differentiated neurons of ChAc patients compared to healthy donors. RT-PCR showed a 
significant decrease in the mRNA levels of Orai1 and STIM1 in iPSC-differentiated neurons 
of ChAc patients. Apoptosis was detected by annexin-V / propidium iodide staining via flow 
cytometry and was in fibroblasts and iPSC-differentiated neurons of ChAc patients 
significantly higher than in those of healthy donors. 
In this study, it could be shown that the treatment of fibroblasts and neurons of ChAc patients 
with lithium positively influenced SOCE, an effect significantly reduced by the Orai1 
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blocker, 2-aminoethoxy diphenyl borate (2-APB). Lithium induced a significant decrease in 
apoptosis, an effect again abrogated by 2-APB. 
The mRNA and protein expression of Orai1 and STIM1 were increased by lithium, an effect 
reversed by inhibition of SGK1 and NFкB. 
In conclusion, the apoptotic effect of chorein deficiency in fibroblasts and neurons of ChAc 
patients is in part due to the decreased expression of Orai1, STIM1 and SOCE. Treatment 
with lithium could reverse this effect, via the SGK1/NFкB signaling pathway, which shows 
that lithium could be a new treatment for Chorea Acanthocytosis. 
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 Introduction 
1. Introduction 
 
1.1 Chorea Acanthocytosis (ChAc) 
 
1.1.1 Background, diagnosis and therapy 
 
Chorea Acanthocytosis (ChAc) is a fatal neurodegenerative disease characterized by red 
blood cell acanthocytosis and loss of striatal neurons as a hallmark like other 
neurodegenerative diseases (Jung et al., 2011). It progresses to cause premature death of the 
patient (Jung et al., 2011). Autosomal-recessive ChAc is caused by a loss-of-function 
mutation in the vacuolar protein sorting 13 homolog A (VPS13A) gene leading to a lack of 
the functional respective encoded protein chorein (Velayos-Baeza et al., 2004, Dobson-Stone 
et al., 2004). 
This disease could be diagnosed by several procedures. The first diagnostic step for ChAc is 
to evaluate the levels of muscle creatine kinase (CK), as well the serum concentrations of 
liver enzymes lactate dehydrogenase (LDH), alanine transaminase (ALT) and aspartate 
transaminase (AST) which have shown to be increased in ChAc patients (Velayos Baeza et 
al., 1993). The molecular genetic diagnosis of the disorder will be by sequencing the gene 
VPS13A. This gene is located on the long (q) arm of chromosome 9 at the position 21.2 
(9q21,2) and it is relatively a big gene of 73 exons which has two main splice forms or 
transcripts: transcript A (exons 1-68 and 70-73), and transcript B (exons 1-69) (Rampoldi et 
al., 2001, Dobson-Stone et al., 2004). Expression of transcript A in full exons is required for a 
full-length chorein (Dobson-Stone et al., 2004). The big size of the VPS13A gene makes the 
screening for mutations is a hefty and time-consuming procedure to reach the right diagnosis 
of Chorea Acanthocytosis, therefore an easier diagnostic method could be the cellular 
detection of chorein by western blot analysis of patient erythrocytes, which shows a missed 
chorein protein band in patients samples and thus gives an early indication of the disorder, a 
differential diagnosis that will not be found in patients of Huntington’s disease or McLeod 
syndrome (Dobson-Stone et al., 2004) (Figure 1).  
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Figure 1: Absence of chorein 
protein. 
Western blot demonstrating the 
absence of chorein protein band 
in a sample from ChAc patient. 
The figure is used after 
permission from (Walker, 2015). 
 
 
 
 
 
 
The blood of most ChAc patients will contain a highly variable percentage of acanthocytes, 
between 5%-50% of the red blood cell population (Rampoldi et al., 2002) (Figure 2). 
 
Figure 2: Acanthocytosis in the blood of ChAc patient. 
Scanning electron microscopy of erythrocytes from ChAc patient’s peripheral blood that shows the 
presence of acanthocytosis (scale bar in A: 1 µm; in B: 10 µm). The figure is used after permission 
from (Zhang et al., 2013). 
 
On the other hand, the clinical characteristics could give also a certain diagnose of the 
disorder; which include dystonia that will affect the oral region and tongue especially, as 
tongue and lip biting that, in turn, leads to dysarthria and dysphagia and ends with weight loss 
(Bader et al., 2010). Other clinical diagnostic features include seizures and epilepsy (Scheid 
et al., 2009), myopathy, characterized by distal muscle wasting and weakness and 
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amyotrophy, subtle eye movement abnormalities and movement disorder as limb chorea  
(Velayos Baeza et al., 1993). 
The current treatment of Chorea Acanthocytosis is only symptomatic and supportive, as 
Botulinum toxin injections for relaxing the muscles and to control the oro-lingual dystonia 
(Schneider et al., 2006) and other drugs to relieve the psychiatric and movement symptoms 
(Velayos Baeza et al., 1993). 
 
1.1.2 Chorein and its role 
 
Chorein is a large protein, more than 3000 amino acids with a predicted molecular weight of 
360 kDa (Ueno et al., 2001, Dobson-Stone et al., 2004), expressed highly in tissues like testis, 
kidney, spleen and brain and less in lungs, liver and placenta (Kurano et al., 2007, Ueno et 
al., 2001) as well in many cell types including vascular endothelial cells (Alesutan et al., 
2013), neuronal cells (Hayashi et al., 2012), platelets (Schmidt et al., 2013), erythrocytes and 
skin fibroblasts (Dobson-Stone et al., 2004).  
It has essential roles in the cell, and many cellular functions are chorein-sensitive such as, 
dopamine release (Honisch et al., 2015a), endothelial cell stiffness (Alesutan et al., 2013), 
cytoskeletal architecture (Honisch et al., 2015b) and survival of tumor cells, neurons and 
skeletal muscle cells (Velayos Baeza et al., 1993, Saiki et al., 2007, Honisch et al., 2015c). 
Furthermore, chorein has a function on regulation the secretion and aggregation of blood 
platelets according to a previous study which showed that lack of chorein in platelets of 
ChAc patients leads to significantly reducing the expression of vesicle-associated membrane 
protein 8 (VAMP8), an important protein for secretion of platelets granules (Polgar et al., 
2002, Schmidt et al., 2013). 
In a previous study, erythrocytes of ChAc patients showed a decreased level of 
phosphorylation of the p21 protein-activated kinase 1 (PAK1) and depolymerization of 
cortical actin, which reflects the role of chorein on regulation cytoskeletal architecture (Foller 
et al., 2012, Honisch et al., 2015b). Moreover, chorein silencing resulted in decreasing the 
phosphorylation of Bcl-2-associated death protein (Bad) and this led to prompt apoptosis by 
causing the mitochondrial depolarization as well DNA fragmentation and exposure of 
phosphatidylserine at the cell surface, all hallmarks for apoptosis, which confirm the effect of 
chorein in cell survival (Foller et al., 2012). 
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According to proteome analysis, there was found a binary protein-protein interaction between 
chorein and phosphoinositide-3-kinase (PI3K) (Wu et al., 2007, European Molecular Biology 
Laboratory, 2011), moreover, lack of chorein leads to decreased level of the activation and 
phosphorylation of p85 subunit of phosphoinositide-3-kinase (PI3K) (Foller et al., 2012).  
The PI3K plays a crucial role in many critical pathways for cell survival and cell growth 
which are both sensitive to Ca2+ signaling (Orrenius et al., 2003, Burgoyne, 2007, 
Vanhaesebroeck et al., 2012). The next parts will describe the mechanism of this crucial 
signaling pathway, its role and how does this kinase affect Ca2+ signals. 
 
1.2 Calcium signaling 
 
1.2.1 Importance and basics 
 
Intracellular calcium is known as one of the most important cellular signals in many 
mechanisms such as fertilization, cell motility, gene transcription, secretion, apoptosis and 
necrosis (Berridge, 1993, Carafoli, 2002, Berridge et al., 2003). In neuronal functions as 
particular, Ca2+ signaling has a dominant role in gene expression, neuronal growth, 
neurotransmission, survival and death (Orrenius et al., 2003, Burgoyne, 2007). 
The system of Ca2+-signaling has a basic common component in all cell types, that to perform 
brief pulses between external medium and intracellular store using a pack of molecules that 
work together to achieve the signal (Berridge et al., 2000, Berridge et al., 2003).  
Ca2+ could be released from its intracellular stores, the endoplasmic reticulum (ER) or the 
sarcoplasmic reticulum (SR), as a reaction to many stimulants (Koch, 1990, Berridge, 1993). 
These stimulants, such as insulin or growth factors, when interacting with cell surface 
receptors, for example, G protein-coupled receptors (GPCRs) or receptor of tyrosine kinases 
(RTKs), induce the activation of two important players in the process of Ca2+ release, 
phospholipase Cγ (PLCγ) and PI3K (Rhee and Bae, 1997, Katan, 1998, Bootman et al., 2002, 
Putney and Tomita, 2012, Vanhaesebroeck et al., 2012). After activation, PLCγ and PI3K 
work in related pathways: On the one hand, activation of PLCγ leads to hydrolysis the 
signaling lipid phosphatidylinositol 4,5-bisphosphate (PtdIns-4,5-P2) (PIP2) to form 
diacylglycerol (DAG) and inositol-1,4,5-triphosphate (In3P) (Clapham, 1995). In3P then 
binds to its receptor, inositol-1,4,5-triphosphate receptors (In3PR), on ER and triggers the 
release of calcium (Clapham, 1995). On the other hand, when PI3K is activated, it 
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phosphorylates (PIP2) into phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3) (PIP3) 
which in turn feeds back to enhance again the PLCγ to catalyze the breakdown of PIP2 to 
In3P and DAG (Scharenberg and Kinet, 1998). 
Calcium enters into the cell by a capacitative mechanism, i.e. when the intracellular stores of 
calcium are empty, this sends a signal to the membrane of the cell and activates calcium 
influx in order to refill the stores (Putney, 1986, Takemura et al., 1989). This signal was 
understood after the finding of Stromal Interacting Molecule 1 (STIM1) which was described 
as the sensor of calcium in the ER (Roos et al., 2005, Liou et al., 2005), and the other player 
to complete the mechanism was Orai1-3, the pore-forming subunit of calcium channels in the 
cellular membrane (Feske et al., 2006, Vig et al., 2006b, Zhang et al., 2006). Capacitative 
calcium entry and Store-operated calcium entry (SOCE) are two names of one mechanism. 
Hoth and Penner also explained that depletion of calcium stores leads to an 
electrophysiological inward current, highly selective to calcium, and caused by activation of 
Ca2+ channels, which they called calcium release-activated calcium current (ICRAC) (Hoth and 
Penner, 1992). 
 
1.2.2 STIM1 
 
STIM1 was known and described at first as a tumor suppressor gene (Parker et al., 1996), 
until the demonstration of Roos et al., and Liou et al. at 2005 that STIM1 is a component of 
homeostasis for Ca2+ signals (Roos et al., 2005, Liou et al., 2005). In Drosophila S2 cells 
there was found a single Stim gene (dstim) (Roos et al., 2005), but in mammalian HeLa cells 
were two human homologs found for dstim, STIM1 and STIM2 (Liou et al., 2005). The 
physiological function of STIM2 is controversial as it didn’t show the same effect on ICRAC in 
all cell lines (Putney, 2007). 
STIM1 is composed of 685 amino acids and is located in the membrane of the ER via a 
transmembrane domain, that when Ca2+ concentration is low, a conformational change acts 
on the domains and causes the ICRAC activation (Roos et al., 2005, Liou et al., 2005, Zhang et 
al., 2005b). 
STIM1 molecule has three coiled-coil domains: the intracellular C terminal contains the 
second and third coiled-coil domains which make together the so-called; CRAC activating 
domain (CAD) as it is responsible to activate the Orai1 channel (Park et al., 2009), while the 
domain in the luminal of ER is at the N-terminal and contains a signal peptide that senses the 
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concentration of Ca2+ in the ER store leading to a change in the structure of STIM1 domains, 
and results in oligomerization of several STIM1 molecules followed by activation of SOCE 
(Liou et al., 2005, Zhang et al., 2005b, Soboloff et al., 2006, Stathopulos et al., 2006, Mercer 
et al., 2006, Wu et al., 2006) (Figure 3). 
The C-terminus has also the CRAC modulatory domain (CMD) that senses the negative 
response to Ca2+ influx and leads to stopping the activation of Orai1 channel and inactivation 
of ICRAC (Park et al., 2009). 
 
1.2.3 Orai1 
 
Feske et al described Orai1 as a crucial Ca2+ channel for ICRAC (Feske et al., 2006). This was 
proved by the genetic mapping of severe combined immunodeficiency (SCID) patients whose 
ICRAC was defective, which showed a mutation in the Orai1 protein that caused the 
hydrophobicity of the channel, and led to the defective ICRAC (Feske et al., 2006). On the 
other hand, knockdown of dstim and dorai in Drosophila induced complete inhibition of 
ICRAC (Feske et al., 2006).  
In Drosophila, dorai was identified and had three human homologs, Orai1, Orai2 and Orai3, 
or CRACM1, CRACM2, CRACM3 as they were also named (Feske et al., 2006, Vig et al., 
2006b, Zhang et al., 2006). Orai2 and Orai3 function like Orai1 but their Ca2+ currents are 
smaller and sometimes undetectable (Mercer et al., 2006). This was noticed after 
overexpression of STIM1 with Orai2 or Orai3 which resulted in either a slight increase or no 
effect on ICRAC (Mercer et al., 2006).  
The Ca2+ channel is made up of Orai1 tetramer (Ji et al., 2008, Mignen et al., 2008, Penna et 
al., 2008). Orai1 is a protein of 301 amino acids consists of four transmembrane domains 
(TM) located in the plasma membrane and connected by one intracellular and two 
extracellular loops with its N and C terminus are in the cytoplasm (Hou et al., 2012). The N- 
and C- terminus of Orai1 are both important for the activity of the channel and they both have 
the functional binding sites for activated STIM1 (Muik et al., 2008, Palty et al., 2015). Never 
the less, the C-terminus of Orai1 binds to STIM1 stronger than N-terminus, and deleting the 
C-terminus will barrier Orai1 from interacting with STIM1 (Muik et al., 2008). The N-
terminus contains a calmodulin binding domain (CBD) (Mullins et al., 2009) which is 
important for the mechanism calcium-dependent inactivation (CDI) to keep cytosolic Ca2+ 
concentration low when the cell is at the resting situation (Roos et al., 2005) (Figure 3). 
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Figure 3: Model of Orai1 and STIM1. 
Orai1 has four transmembrane domains (TM), with its N- and C- terminus localized in the cytoplasm 
and involves two extracellular loops and one intracellular loop; the TM1 has the glutamic acid 106 
(E106) which is identified as the Ca2+-binding amino acid and the selectivity filter of the CRAC 
channel (Prakriya et al., 2006, Vig et al., 2006a, Gwack et al., 2007, McNally et al., 2009, Zhou et al., 
2010). The intracellular C-terminus includes the coiled-coil (CC) domain, which binds to STIM (Li et 
al., 2007, Muik et al., 2008, Yuan et al., 2009). STIM1 has one transmembrane domain in the ER 
membrane. The N-terminus has Ca2+ binding EF-hand domain that represents the sensor of 
Ca2+ concentration in the ER and interacts with the SAM (sterile alpha motif) domain to result in the 
oligomerization of several STIM1 molecules (Stathopulos et al., 2006, Luik et al., 2008, Muik et al., 
2011). The C-terminus contains the CRAC activation domain (CAD) that interacts with Orai1and 
activates the CRAC channel, and the end of the C-terminus has lysine (K) -rich domain which allows 
the interaction with plasma membrane lipids (PIP2) and (PIP3) (Liou et al., 2007, Feske et al., 2012). 
Figure adapted from (Feske et al., 2012), changed. 
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1.2.4 Formation of ICRAC 
 
When STIM1 senses the depletion of Ca2+ in the ER by its N-terminal luminal domain, this 
results in the conformational change of STIM1 into oligomers (dimers, tetramers…) followed 
by its migration to be near the plasmatic membrane and binding to the C terminus of Orai1. 
Then Orai is pulled to form the puncta between ER and plasma membrane, which ends with 
opening Orai1 channel by its N-terminus followed by Ca2+ entry into the ER (Liou et al., 
2005, Hogan et al., 2010) (Figure 4). 
 
Figure 4: Steps of store-operated Ca2+ entry.  
(A) Resting state where STIM1 is a monomer, Orai1 as an oligomer (probably a tetramer) and ER 
Ca2+ stores are filled with Ca2+, (B) ER Ca2+ stores are depleted and STIM1 oligomerization starts and 
forms oligomers (dimers for example), (C) migration of STIM1 to ER-plasma membrane appositions 
and binding the STIM1 lysin (K)-rich regions to lipids in the plasma membrane, as well, STIM1 
oligomers bind to the C-terminal of Orai1 and recruit it to the ER-plasma membrane junctions, (D) 
Orai1 channel is opened and Ca2+ enters the cell (Li et al., 2007, Muik et al., 2008, Park et al., 2009, 
Yuan et al., 2009, Kawasaki et al., 2009, Muik et al., 2009, Hogan et al., 2010). Figure adapted from 
(Hogan et al., 2010), changed.  
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1.3 Effect of lithium on cell survival and neurodegenerative diseases 
 
Lithium is one of the oldest psychiatric treatments since the 19th and till now, and its benefits 
were known for reducing the risk of suicide and mortality in mood disorders as mania (Cade, 
1949), aggressive behavior (Sheard et al., 1976, Muller-Oerlinghausen and Lewitzka, 2010) 
depression (Crossley and Bauer, 2007) and bipolar disorder (BD) (Alda, 2015). 
It also batters neurodegeneration in many diseases such as Huntington’s disease, Parkinson’s 
disease, Alzheimer’s disease, amyotrophic lateral sclerosis (Alvarez et al., 2002, Lazzara and 
Kim, 2015, Bauer et al., 2003) and spinocerebellar ataxias type 1 and 3 (Watase et al., 2007).  
The plasma levels that were needed for a full clinical effect of lithium is between 0.6 and 
1 mmol/L (Alda, 2015). 
The importance of lithium comes from its beneficial effects on basic characters of mood and 
neurodegenerative disorders reducing neuronal excitability and neuronal death. 
On the one hand, lithium ions reduce the resting membrane potential and neuronal 
excitability, which increases during the episodes of the illness, by reducing intracellular 
sodium and calcium via voltage-gated sodium channels (Schou, 1957, Huang et al., 2007, 
Gao et al., 2010). 
On the other hand, it has a neuroprotective effect achieved by many mechanisms: Lithium 
can inhibit glycogen synthase kinase-3 (GSK-3) at concentrations 1-2 mM either directly, by 
competition for a magnesium-binding site with GSK-3, or indirectly by Akt (serine/threonine 
kinase or protein kinase B as also known) activation which leads to further inhibiting the 
proapoptotic forkhead box class O transcription factor (Foxo3a), Bcl-2-associated death 
protein (Bad) and murine double minute (MDM) (Jope, 1999, Beaulieu et al., 2004, Avila et 
al., 2012, Lazzara and Kim, 2015). Another mechanism is by regulating pro-apoptotic 
proteins as Blc-2-associated X protein (Bax), which binds and antagonizes Bcl-2 protein to 
prompts apoptosis, and the tumor suppressor protein p53 which targets both Bcl-2 and Bax 
and promotes cell death (Lazzara and Kim, 2015, Basu and Haldar, 1998). Lithium also 
activates the up-regulation of brain-derived neurotrophic factor (BDNF) which boosts the 
survival and plasticity of neurons (McAllister et al., 1999, Lazzara and Kim, 2015), in 
addition, it increases the levels of Bcl-2 protein which provide the anti-apoptotic activity 
(Youdim and Arraf, 2004). Moreover, lithium is able to be an anti-oxidant as it increases the 
levels of GSH in neurons, the glutathione that decreases when oxidative stress occurs in the 
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neurons and leads to increase the cellular levels of hydrogen peroxidase and thus induces cell 
death (de Vasconcellos et al., 2006, Kim et al., 2011). 
 
1.4 Aim of the study 
 
The aim of this study is to understand the pathophysiology of Chorea Acanthocytosis (ChAc) 
and to test if it is paralleled with neuronal regulation of Ca2+ release-activated Ca2+ channels 
Orai1, and/or its regulator STIM1 in order to identify potential therapeutic targets for the 
treatment of ChAc. 
After the success that lithium has shown on neuroprotection and reducing mortality in bipolar 
disease, Alzheimer’s disease and Parkinson’s disease, the hypothesis was if lithium will have 
the same protecting effect on Chorea Acanthocytosis and could be a therapy for these 
patients. 
The experiments were performed on fibroblasts and iPSC-differentiated neurons from ChAc 
patients and were compared with samples from healthy donors to: 
 Understand the pathophysiology of Chorea Acanthocytosis  
 As SOCE is an important player in cell protection, would it be affected or play a role in 
Chorea Acanthocytosis? 
 Would lithium be a possible therapy to protect neuronal and cell death in 
Chorea Acanthocytosis?  
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2. Materials 
 
2.1 Chemicals 
Name  Company name and country of origin 
30% Acrylamide Mix Carl Roth, Karlsruhe, Germany 
Ammonium persulfate Carl Roth, Karlsruhe, Germany 
Bio-Rad Protein Assay Dye Reagent Bio-Rad, München, Germany 
Calcium chloride (CaCl2) Sigma Aldrich, St. Louis, USA 
Chloroform Carl Roth, Karlsruhe, Germany 
Developer and Replenisher Kodak, USA 
DMEM (1X) + GlutaMax™ -1 Gibco, Paisley, UK 
DMSO  Carl Roth, Karlsruhe, Germany 
Dulbecco’s Phosphate Buffered Saline (DPBS) Sigma-Aldrich, St. Louis, USA 
EGTA Roth, Karlsruhe, Germany 
Ethanol 99% Carl Roth, Karlsruhe, Germany 
Fetal calf serum (FCS) Thermo Fisher Scientific, Waltham, 
Massachusetts 
Fixer and Replenisher Kodak, USA 
Fura-2/AM Invitrogen, Goettingen, Germany 
Glucose Sigma Aldrich, St. Louis, USA 
Glycine Carl Roth, Karlsruhe, Germany 
GSK-650394 Sigma-Aldrich, St. Louis, USA 
Isopropyl alcohol Carl Roth, Karlsruhe, Germany 
Lithium chloride Sigma-Aldrich, St. Louis, USA 
Magnesium sulfate (MgSO4) Sigma Aldrich, St. Louis, USA 
Methanol Sigma-Aldrich, St. Louis, USA 
Non-fat milk powder Carl Roth, Karlsruhe, Germany 
Penicillin/Streptomycin Invitrogen, Karlsruhe, Germany 
PeqGold protein marker PeqLab, Erlangen, Germany 
PeqGold TriFast PeqLab, Erlangen, Germany 
PMSF Sigma-Aldrich, St. Louis, USA 
Potassium chloride (KCl) Carl Roth, Karlsruhe, Germany 
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RIPA lysis buffer Cell Signaling Technology, USA 
Roti®-Load 1 (4x) Carl Roth, Karlsruhe, Germany 
SDS Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium hydrogen phosphate (Na2HPO4) Roth, Karlsruhe, Germany 
Roti®-Free Stripping Buffer Carl Roth, Karlsruhe, Germany 
TEMED Carl Roth, Karlsruhe, Germany 
Thapsigargin Invitrogen, Darmstadt, Germany 
Tris-base Carl Roth, Karlsruhe, Germany 
Trypsin-EDTA Gibco, Paisley, UK 
Tween 20 Carl Roth, Karlsruhe, Germany 
Wogonin hydrate Sigma-Aldrich, St. Louis, USA 
 
2.2 Antibodies 
Antibody Source Manufacturer 
Anti-GAPDH antibody Rabbit Cell Signaling Technology, USA 
Anti-Orai1 antibody Rabbit Cell Signaling Technology, USA 
Anti-STIM1 antibody Rabbit Cell Signaling Technology, USA 
Anti-rabbit HRP-conjugated antibody Cell Signaling Technology, USA 
 
2.3 Primers 
Gene Sequence 
Orai1 – fwd CGTATCTAGAATGCATCCGGAGCC 
Orai1 – rev CAGCCACTATGCCTAGGTCGACTAGC 
STIM1 – fwd CCTCGGTACCATCCATGTTGTAGCA 
STIM1 – rev GCGAAAGCTTACGCTAAAATGGTGTCT 
GAPDH – fwd TGAGTACGTCGTGGAGTCCAC 
GAPDH – rev GTGCTAAGCAGTTGGTGGTG 
 
2.4 Kits 
GoScript™ Reverse Transcription System Promega, Hilden, Germany 
GoTaq® qPCR Master Mix Promega, Hilden, Germany 
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ECL detecting reagents Amersham, Freiburg, Germany 
eBioscience™ Annexin V Apoptosis Detection 
Kit FITC 
Thermofisher Scientific, San Diego, USA 
2.5 Solutions and Buffers 
 
Table 1. Resolving gel (10%) 
Component volumes (ml) per 5 ml gel mold volume 
H2O 1.9 
30% Acrylamide Mix 1.7 
1.5 M Tris (pH 8.8) 1.3 
10% SDS 0.05 
10% ammonium persulfate 0.05 
TEMED 0.002 
 
Table 2. Stacking gel (5%) 
Component volumes (ml) per 1ml gel mold volume 
H2O 0.68 
30% Acrylamide Mix 0.17 
1.0 M Tris (pH 6.8) 0.13 
10% SDS 0.01 
10% ammonium persulfate 0.01 
TEMED 0.004 
 
Table 3. Running buffer (10X) 
Tris base 250 mM 
Glycine 1.9 M 
SDS 1% 
dH2O Up to 1 liter 
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Table 4. Transfer buffer 
Tris base 198 mM 
Glycine 1.5 M 
dH2O Up to 1 liter 
 
Table 5. TBS (10X) 
Tris base 200 mM 
NaCl 1.3 M 
dH2O Up to 1 liter, pH 7.6 
TBS 1X was prepared using dH2O and 1% Tween 20 was added to get at the end TBST 1X. 
 
Table 6. Standard Ringer solution (pH 7.4) 
Components in mM: 
NaCl 125  
KCl 5  
MgSO4 1.2  
CaCl2 2  
Na2HPO4 2  
HEPES 32  
Glucose 5  
d.H2O To reach 1 liter 
 
Table 7. Ca2+-free Ringer solution (pH 7.4) 
Components in mM: 
NaCl 125 
KCl 5 
MgSO4 1.2 
Na2HPO4 2 
HEPES 32 
EGTA 0.5 
Glucose 5 
d.H2O To reach 1 liter 
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2.6 Equipment 
Name Company name and country origin 
Amersham hyper film GE Healthcare, München, Germany 
Agarose gel electrophoresis chamber BioRad, München, Germany 
Axiorvert 100  Carl Zeiss, Oberkochen, Germany 
BioPhotometer Eppendorf, Hamburg, Germany 
Borosilicate glass pipettes Harvard Apparatus, UK 
CFX96 real-time system Bio-Rad Laboratories, Germany 
Cuvettes, Uvette Eppendorf AG, Germany 
DMZ puller Zeitz, Augsburg, Germany 
Electrophoresis and blotting system Bio-Rad Laboratories, Germany 
EPC 9 amplifier Heka, Lambrecht, Germany 
Pipette 0,5/10, 10/100, 100/1000 LABMATE Optima, Germany 
Flow cytometry machine, FACS Calibur™ BD Biosciences, USA 
Heraeus cell culture hood Thermo Fisher Scientific, USA 
Heraeus cell culture incubator Thermo Fisher Scientific, USA 
Amersham Hyperfilm™ ECL  GE Healthcare Limited, UK 
MS31 electrical micromanipulator MW, Märzhäuser, Wetzlar, Germany 
Vortex Scientific Industries, USA 
Pipette man, pipetus®  Hirshmann Laborgerate, Germany 
pH meter Sartorius, Göttingen, Germany 
Corning® Costar® Stripette® serological 
pipettes 5, 10, 25 ml 
Corning Incorporated, Corning NY, USA 
SterileTubes 15, 50 ml Greiner bio-one, Germany  
Sterile Tips 10, 100, 200, 1000 µl Biozyme, USA 
Cell Culture plate 6, 12, 24, 96 well Costar, USA 
Tissue Culture Flask 75ml SARSTEDT, Germany 
qPCR 96 well plate Peqlab, Erlangen, Germany 
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3. Methods  
 
3.1 Cells 
 
The study has been approved by the Ethical Commission of the University of Tübingen 
(598/2011) and by the Institutional Review Board of the Technische Universität Dresden 
(EK45022009). Informed consent was obtained from all participants and/or their legal 
guardian/s. 
 
3.1.1 Isolation of fibroblast from skin biopsies 
 
Skin biopsies were isolated from ChAc patients (n=6) and healthy donors (n=6). The biopsies 
were minced by sterile techniques, washed twice in PBS supplemented with antibiotics (100 
U/ml penicillin and 100 mg/ml streptomycin) and cultivated in fibroblast medium DMEM 
(Biochrom, Berlin, Germany) supplemented with 10% FCS and antibiotics (100 U/ml 
penicillin and 100 mg/ml streptomycin) and maintained at 37°C in a humidified atmosphere 
of 5% CO2 and 95% air until fibroblast grew out of the biopsy. To detach the established 
fibroblasts, trypsin 0.25% and 0.05% EDTA were used for 5 min and the separated cells were 
aliquoted and the aliquots were cultured again with the same previously described medium. 
Cells between passage three and twelve were used for the study. 
 
3.1.2 Generation of induced pluripotent stem cells (iPSCs) 
 
The generation of iPSCs was according to the published protocol (Okita et al., 2011). 
Fibroblasts were obtained from additional patients (n=3) and healthy donors (n=3) (see 
3.1.1). 1x105 of fibroblasts were electroporated using (Nucleofector 2D, Lonza) with a total 
of 1 µg per plasmid which carries the sequences for hOCT4, hSOX2, hKLF4, hL-MYC, and 
hLIN28. After electroporation, fibroblasts were cultivated in fibroblast medium DMEM + 
10% FBS for 1 day, and then the medium was supplemented with 2 ng/ml fibroblast growth 
factor FGF-2 (Peprotech). From day 3 on, cells were cultivated in Essential 8 (E8) medium 
containing 100 µM Na-butyrate (NaB) (Sigma-Aldrich). After 3 – 4 weeks, the iPSC colonies 
were picked manually and expanded in Matrigel-coated 6-well plates. At passage 7 – 10, 
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iPSCs were characterized and frozen in E8 medium supplemented with 40% KOSR (Thermo 
Fisher Scientific), 10% DMSO (Sigma-Aldrich) and 1 µM Y-27632 (Selleckchem, Munich, 
Germany). 
A careful characterization of the generated iPSCs and the establishment of a robust and 
reliable protocol to generate neurons is important to provide consistent phenotypes. For this 
purpose, genomic and functional validation was applied to the generated cells. The genomic 
validation was done using the exclusion of plasmid-integration, SNP array analysis for 
genetic integrity and resequencing of mutation site, and the functional validation was applied 
via confirmation of expression of pluripotency marker and verification of the in vitro 
differentiation potential using a protocol yielding ß-III-tubulin/CTIP-2 positive neurons as 
described in (Hauser et al., 2016). 
 
3.1.3 Neuronal differentiation and treatment of iPSCs 
 
To generate cortical neurons, the previously described protocol was used (Shi et al., 2012). 
To achieve the neural conduction of iPSCs, dual SMAD inhibitors (10 µM SB431542 
(Sigma-Aldrich) and 500 nM LDN-193189 (Sigma-Aldrich)) were added to the 3N medium. 
After 10 days, cells were collected and expanded by cultivation in 3N medium supplemented 
with 20 ng/ml FGF-2 for 2 days. From day 12 on, cells were cultivated in 3N medium with a 
medium change every other day. Cell culture was passaged on day 27 and re-plated 
appropriately for the specific assay. (RNA/Protein isolation & Flowcytometry: 5x105 cells 
per cm2; Ca2+ measurements: 5x104 cells per cm2; Patch clamp: 2.5x105 cells per cm2).  
 
3.2 Treatments 
 
Where indicated, treatment with lithium was done by LiCl solution and cells were treated 
with 2mM. Wogonin and GSK650394 were solved in DMSO and cells were treated with 
(50 µM) and (10 µM) respectively. The solvent did not influence the effects that were 
studied. 
 33 
 
 Methods 
3.3 Quantification of mRNA expression 
 
3.3.1 RNA isolation 
 
Cells were lysed in 500 µl TriFast reagent. 200 µl chloroform was added, heavily mixed and 
incubated in RT for 3 min, then centrifuged at 12000 x g for 15 min at 4°C. The upper layer 
was transferred into a new eppendorf tube and mixed with 250 µl ice-cold Isopropanol and 
incubated for 10 min in RT. The mixture was centrifuged at 12000 x g for 10 min at 4°C. 
After this step the RNA pellet becomes visible and the supernatant was carefully removed. 
500 µl of 70% ice-cold Ethanol was added to wash the pellet then centrifuged at 7000 x g for 
5 min at 4°C. The supernatant was carefully removed, and the pellet was left to air dry for 30 
min in RT then resuspended in 15 µl of RNase-free water for 15 min at 55°C. 
The concentration of the RNA samples was measured using BioPhotometer at λ260 and λ280 
after dilution 1:69 in RNase-free water. 
 
3.3.2 cDNA synthesis 
 
The synthesis was performed using the GoScript™ Reverse Transcription System (Promega) 
according to the manufacturer protocol. After DNase digestion, the volume of 2 µg RNA was 
completed with RNase-free water to reach the volume 10 µl, then 1 µl random primers and 1 
µl oligonucleotides where added and the mix was incubated at 70°C for 5 min, chilled 
directly in 4°C and 4 µl GoScript™ 5X Reaction Buffer, 2 µl of MgCl2, 1 µl PCR Nucleotide 
Mix and 1 µl GoScript™ Reverse Transcriptase was added, mixed and incubated at 25°C for 
5 min, 42°C for 60 min and followed with 70°C for 15 min to inactivate the reverse 
transcriptase. Samples were then either saved at - 20°C or proceeding to the next step. 
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3.3.3 Quantitative PCR 
 
Real-time polymerase chain reaction (RT-PCR) was performed to determine the transcript 
levels of the respective genes. The total reaction mix volume was 15 µl and contained: 1.5 µl 
of cDNA, 7.5 µl of 2x GoTaq® qPCR Master Mix (Promega), 1.5 µl forward and reverse 
primer mix and 4.5 µl nuclease-free water. Then amplification was performed in 96 well 
plates on a CFX96 Real-Time System (Bio-Rad) as the following program: 
1- 95°C for 5 min 
2- 95°C for 10 sec. 
3- 58°C for 20 sec. 
4- 72°C for 25 sec + Plate read 
5- GOTO 2, 40 more times  
6- 95°C for 10 sec. 
7- Melt curve: 60°C to 95°C, increment 0,2°C for 5 sec + Plate read  
 
The Data were analyzed using the ΔΔCT method and the house-keeping gene GAPDH was 
used as an internal control to standardize the mRNA levels of the sample. 
 
3.4 Protein abundance quantification 
 
3.4.1 Protein lysate 
 
The cells were cultured in 6 well plates and treated for the right time accordingly, then 
200 µl/well Trypsin (incubated in 37°C water bath for 15 min) was added to cells and 
incubated in 37°C for 5 min. Then 500 µl/well PBS was added, and the cells were collected 
in eppendorf 1.5 ml tubes, centrifuged (1000 rpm, 5min, Rt) and the pellet was washed twice 
in PBS and then re-suspended in 40 µl ice-cold RIPA lysis buffer containing 1 mM PMSF 
(Sigma Aldrich) and kept in ice for 30 min, This protein lysate was stored in - 80°C or 
proceeded with the next steps.  
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3.4.2 Protein concentration determination 
 
The protein concentration was measured using the Bradford assay (Bio-Rad). For this 
purpose, 2 µl from the protein lysate was mixed with 1 ml of diluted Bradford buffer (the 
Bradford buffer was diluted with distilled H2O 1:5), then the concentration was measured at 
λ595 by the Photometer. The Photometer was calibrated to measure absorbance till 1, and so 
if any sample gave an absorbance over this range, it was diluted with RIPA lysis buffer 
containing 1 M PMSF. 
 
3.4.3 SDS polyacrylamide gel electrophoresis 
 
With the usage of SDS-PAGE, the proteins could be separated according to their molecular 
weight (Laemmli, 1970). And for this result, 100 µg protein were solubilized in Laemmli 
sample buffer (Roti Loading Dye) and cooked at 95°C for 5 min. The gels were prepared (as 
described in Tables 1 and 2) in the gel cassettes (Electrophoresis and blotting system, Bio-
Rad) and the samples were loaded in the wells of the gel. To allocate the right protein size, 
Protein-Marker VI (Peqlab) was loaded in the gel also. The samples were separated by using 
a running buffer (see Table 3) at a voltage of 80 V, and when the proteins were concentrated, 
the voltage was raised to 100 V. 
 
3.4.4 Blotting and protein detection 
 
The proteins were electro-transferred by 100 V onto nitrocellulose membranes for 90 min in 
transfer buffer (see Table 4), and this step was chilled using ice blocks located in the transfer 
tank (Electrophoresis and blotting system, Bio-Rad). The membranes were washed with 
TBST 1X (see Table 5) and then blocked with 5% fat-free milk (Carl Roth) solved in TBST 
for 1 h at RT, then incubated with primary antibody (1:1000 in 1% fat-free milk solved in 
TBST) at 4°C overnight. After incubation, the blots were washed with TBST for 5 min, 3 
times at RT, then incubated with the anti-rabbit HRP-conjugated secondary antibody (1:2000, 
in 1% fat-free milk solved in TBST) for 1 h at RT. Additional washes with TBST were 
applied on the blots for 5 min, 3 times at RT, then the protein bands were detected using ECL 
detection reagents and quantified with Quantity One Software (BioRad, München, Germany) 
or ImageJ. 
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In some cases, the same blot was used to check more than one antibody, and for that purpose, 
the blot was washed, after the first detection, with Roti®-Free Stripping Buffer (Carl Roth) at 
57°C for 30 min, then washed and then incubated with the other wanted primary antibody 
and the same previous protocol was followed. 
 
3.5 Ca2+ measurements 
 
To measure the cytosolic Ca2+ concentration ([Ca2+]i), Fura-2 fluorescence was used. 
Cells were loaded with 2 µM of Fura-2/AM (Invitrogen) for 20-45 min at 37°C. Second, a 
Ringer standard solution (see Table 6) was added to the cells for 3 min and the cells were 
excited at λ340 and λ380 through an objective (Fluor 40x/1.30 oil) related to an inverted 
fluorescence microscope (Axiovert 100). Emitted fluorescence intensity was recorded at λ505, 
and data were acquired every 10 seconds using specialized computer software (Metafluor, 
Universal Imaging, Downingtown, USA). Then to determine SOCE; a Ca2+-free Ringer 
solution (see Table 7) was added to achieve Ca2+-free conditions for 3 min, following comes 
a depletion of intracellular Ca2+-stores using 1 µM of sarco-endoplasmic reticulum Ca2+-
ATPase inhibitor, thapsigargin (Bird et al., 2008), then Ca2+ was added again using the 
Ringer standard solution. 
To quantify Ca2+ entry, the slope (delta ratio/s) and peak (delta ratio) were calculated after 
Ca2+ re-addition. 
 
3.6 Cell death estimation 
 
A normal cell has a phosphatidylserine (PS) layer located in the inner layer of the cell 
membrane, and in apoptosis, the cell membrane becomes ruptured, which enables Annexin to 
enter and bind to PS (Reutelingsperger and van Heerde, 1997, Elmore, 2007). On the other 
hand, in necrotic cell death, the plasma membrane becomes permeable as the nucleic 
membrane, this makes it possible that nucleic acid dyes, such like propidium iodide (PI) to 
bind to the DNA and gives its red fluorescence giving a quantification of necrotic or late 
apoptotic cells (Darzynkiewicz et al., 1997). 
We used a combination of the PS marker, annexin, with the nuclear dye, PI, to detect 
apoptotic and necrotic cells by flow cytometry, and the chemicals of the experiment were 
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from the kit eBioscience™ Annexin V Apoptosis Detection Kit FITC (Thermofisher 
Scientific).  
For this purpose, cells were incubated and treated in 12 well plates, then washed from the 
medium with 200 µl PBS, centrifuged at 1000 rpm for 5 min, then washed with 200 µl of 1X 
annexin washing buffer (AWB), centrifuged and the supernatant trashed. Staining was done 
using 50 µl of AWB containing 1 µl of Annexin V-FITC (Immunotools, Friesoythe, 
Germany) and incubated in dark in 37°C for 15 min. Then 150 µl of AWB was added to the 
cells, the plate was centrifuged, and the supernatant was discarded. After that, the PI staining 
was applied using 200 µl of (AWB) containing 2 µl of PI (Bioscience, Germany) and then 
incubated in dark and 37°C for 8-10 min. After incubation, 200 µl of AWB was added and 
annexin V-FITC, as well as PI fluorescence, was determined by flow cytometry using FACS 
Caliber (BD, Heidelberg, Germany). 
 
Statistics 
Data are expressed as arithmetic means ± SEM. Statistical analysis was done by unpaired t-
test or ANOVA, and results with p < 0.05 were considered as statistically significant. 
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4. Results 
 
4.1 Effect of ChAc on Orai1 abundance 
 
To start the work, Orai1 abundance was compared between fibroblasts of healthy and ChAc 
patients. Thus, after isolating and preparation of fibroblasts from both healthy donors and 
ChAc patients starting from skin biopsies isolation and reaching the step when fibroblasts 
were ready to use, the protein abundance of Orai1 was quantified using western blotting (see 
3.4). Protein was isolated from fibroblasts, separated using SDS-PAGE, and transferred onto 
nitrocellulose membrane and incubated with Orai1 antibody. GAPDH was used as a control 
to uniform the loading of the samples on the gel. And then the membrane was incubated with 
a secondary HRP-conjugated antibody. The results showed that Orai1 protein abundance in 
fibroblasts isolated from ChAc patients was significantly lower than in fibroblasts isolated 
from healthy donors (Figure 5). 
 
Figure 5: Orai1 protein abundance in 
fibroblasts isolated from healthy 
donors and ChAc patients. 
(a) Original western blot of Orai1 protein 
abundance in Fibroblasts isolated from 
healthy donors and ChAc patients. 
(b) Arithmetic means (±SEM, n=5 
healthy donors and 5 patients) of Orai1 
protein abundance in isolated fibroblasts 
from healthy donors (white bar) and 
ChAc patients (black bar). 
** p<0.01 indicates a statistically 
significant difference compared to the 
respective value in fibroblasts isolated 
from healthy donors. Figure adapted 
from (Pelzl et al., 2017a), changed. 
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4.2 Influence of chorein deficiency on intracellular Ca2+ release and 
store-operated calcium entry (SOCE) 
 
Lack of functional Orai1 will affect SOCE (Feske et al., 2006). For checking, Fura-2 
fluorescence was used to measure the cytosolic Ca2+ activity ([Ca2+]i) (see 3.5). First, Ca
2+-
free solution was applied to the cells, then to deplete intracellular Ca2+ stores, a Ca2+-free 
solution containing (1µM) thapsigargin, which is a sarco-endoplasmic reticulum Ca2+ 
ATPase (SERCA) inhibitor, was added, and this led to a rapid transient increase in 
intracellular Ca2+ activity [Ca2+]i similar in both control fibroblasts and healthy fibroblasts 
(Figure 6). Following was the re-addition of extracellular Ca2+ during the maintained 
presence of thapsigargin, and this resulted in a rapid increase of Fura-2 fluorescence in both, 
healthy control and ChAc fibroblasts referring to store-operated Ca2+ entry (SOCE) 
(Figure 6). As shown in (Figure 6), the peak of SOCE in fibroblasts isolated from ChAc 
patients was significantly lower than in fibroblasts isolated from healthy donors. 
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Figure 6: Difference of intracellular Ca2+ release and store-operated Ca2+ entry in fibroblasts 
isolated from healthy donors and ChAc patients.  
 (a) Representative tracings of Fura-2 fluorescence-ratio in fluorescence spectrometry during Ca2+-
free conditions with the presence of thapsigargin (1 µM), and then after re-addition of extracellular 
Ca2+ in fibroblasts isolated from healthy donors and ChAc patients. (b,c) Arithmetic means (±SEM, 
n=48-61 cells from 4-5 individuals) of peak (b) and slope (c) increase of Fura-2 fluorescence-ratio 
after the addition of thapsigargin into Ca2+-free conditions in fibroblasts isolated from healthy donors 
and ChAc patients. (d,e) Arithmetic means (±SEM, n=48-61 cells from 4-5 individuals) of peak (b) 
and slope (c) increase of Fura-2 fluorescence-ratio after the re-addition of extracellular Ca2+ in 
fibroblasts isolated from healthy donors and ChAc patients. ** p<0.001 indicates a statistically 
significant difference compared to the respective value in fibroblasts isolated from healthy donors. 
Figure adapted from (Pelzl et al., 2017a), changed. 
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4.3 Lithium treatment restores SOCE in fibroblasts isolated from ChAc 
patients 
 
To explore the validity of the hypothesis about lithium, fibroblasts isolated from ChAc 
patients were treated with lithium (24 hours, 2 mM) and then Fura-2 fluorescence-ratio was 
employed to check if there will be any difference on intracellular Ca2+ activity or store-
operated Ca2+ entry (SOCE) (see 3.5). Exposure of the cell to Ca2+-free solution containing 
thapsigargin (1 µM), the sarco-endoplasmic reticulum Ca2+/ATPase (SERCA) inhibitor, was 
used to deplete intracellular Ca2+ stores. This leads to an increase of intracellular Ca2+ activity 
which was significantly higher in ChAc patients-isolated fibroblasts treated with lithium 
(24 hours, 2 mM) than untreated ChAc fibroblasts (Figure 7). Then re-addition of 
extracellular Ca2+ in the continued presence of thapsigargin gave a rapid increase of Fura-2 
fluorescence reflecting SOCE, which was in fibroblasts treated with lithium (24 hours, 
2 mM) again significantly higher than untreated ChAc fibroblasts (Figure 7). 
To go deeper, fibroblasts were treated with Orai1 blocker 2-Aminotheoxydiphenyl Borat (2-
APB) (50 µM) together with lithium (2 mM) for 24 hours and the results showed that both 
slope and peak of SOCE in fibroblasts isolated from ChAc patients were significantly 
decreased by 2-APB treatment (Figure 7). 
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Figure 7: Effect of lithium treatment on fibroblasts isolated from ChAc patients without and 
with additional treatment with Orai1 blocker 2-APB. 
 (a) Representative tracings of Fura-2 fluorescence-ratio in fluorescence spectrometry before and after 
removal of extracellular Ca2+ and depletion of intracellular Ca2+ stores by thapsigargin (1 µM) and 
then followed by re-addition of extracellular Ca2+ in the continued presence of thapsigargin in 
fibroblasts isolated from ChAc patients untreated or treated with lithium (24 hours, 2 mM) alone or 
treated with both lithium (2 mM) and 2-APB (50 µM) together for 24 hours. (b,c) Arithmetic means 
(±SEM, n=23-73 cells from 4-5 individuals) of peak (b) and slope (c) increase of Fura-2 fluorescence-
ratio after the addition of thapsigargin (1µM) in fibroblasts isolated from ChAc patients without 
treatment or treated with lithium (24 hours, 2 mM) alone or treated with both lithium (2 mM) and 
2-APB (50 µM) together for 24 hours. (d,e) Arithmetic means (±SEM, n=23-73 cells from 4-5 
individuals) of peak (d) and slope (e) increase of Fura-2 fluorescence-ratio after the re-addition of 
extracellular Ca2+ in fibroblasts isolated from ChAc patients without treatment or treated with lithium 
(24 hours, 2 mM) alone or treated with both lithium (2 mM) and 2-APB (50 µM) together for 
24 hours. * P<0.05, ** p<0.01 indicates a statistically significant difference compared to the 
respective value of untreated ChAc fibroblasts. §§ p<0.01 indicates a statistically significant 
difference compared to the respective value of ChAc fibroblasts treated with lithium alone. Figure 
adapted from (Pelzl et al., 2017a), changed. 
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4.4 Effect of chorein deficiency on the survival of fibroblasts isolated 
from healthy donors and ChAc patients 
 
To test if the difference in Ca2+ signaling between healthy and ChAc fibroblasts is paralleled 
by differences in apoptosis also, flow cytometry quantification was used (see 3.6). 
To identify phosphatidyl exposing cells, annexin-V-binding was utilized, while propidium 
iodide was used to identify cells with the permeable cell membrane. The results showed that 
the percentage of annexin-v-binding fibroblasts that are isolated from ChAc patients was 
significantly higher than the percentage of annexin-V-binding fibroblasts that are isolated 
from healthy donors (Figure 8). Furthermore, the percentage of propidium iodide-stained 
cells changed between healthy and ChAc fibroblasts, and this percentage was in fibroblasts 
isolated from ChAc patients significantly higher than healthy donors’ fibroblasts (Figure 8). 
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Figure 8: difference in phosphatidylserine translocation and propidium iodide uptake between 
fibroblasts isolated from healthy donors and fibroblasts isolated from ChAc patients. 
 (a,b) Representative dot blots of propidium iodide harboring versus annexin-V- binding in fibroblasts 
isolated from healthy donors and ChAc patients. (c) Arithmetic means (± SEM, n=4-5 individuals) of 
annexin-V-binding fibroblasts isolated from healthy donors and from ChAc patients and both 
expressed in the percentage of the value in healthy donors. (d) Arithmetic means (± SEM, n=4-5 
individuals) of propidium iodide harboring fibroblasts isolated from healthy donors and from ChAc 
patients and both expressed in the percentage of the value in healthy donors. * p<0.05, ** p<0.01 
indicates a statistically significant difference compared to the respective value in fibroblasts isolated 
from healthy donors. Figure adapted from (Pelzl et al., 2017a), changed. 
 
4.5 Lithium treatment leads to survival of fibroblasts isolated from ChAc 
patients  
 
To explore if the lithium treatment will make any difference in isolated fibroblasts apoptosis, 
again phosphatidylserine translocation utilizing annexin-V-binding and propidium iodide 
uptake was measured. As a result, after lithium (24 hours, 2mM) treatment on fibroblasts 
isolated from ChAc patients, the percentage of annexin-V-binding fibroblasts as well 
propidium iodide harboring fibroblasts decreased significantly compared to untreated 
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fibroblasts. Treatment of fibroblasts isolated from ChAc patients with Orai1 blocker 
2-APB (50µM), increased significantly the percentage of both, annexin-V-binding and 
propidium iodide staining. Treatment with both lithium and 2-APB didn’t result in a 
significant decrease in annexin-V-binding or propidium iodide staining fibroblasts (Figure 9). 
 
Figure 9: Effect of lithium on phosphatidylserine translocation and propidium iodide uptake in 
fibroblasts isolated from healthy donors and ChAc patients without and with Orai1 blocker 
2-APB. 
(a-e) Representative dot blots of propidium iodide staining versus annexin-V-binding fibroblasts 
isolated from healthy donors, untreated ChAc patients or treated with lithium (24 hours, 2mM) alone, 
or treated with Orai1 blocker 2-APB (24 hours, 50 µM) alone, or treated with both, lithium (2 mM) 
and 2-APB (50 µM) together for 24 hours. (f) Arithmetic means (±SEM, n=4-5 individuals) of 
percentage of annexin-V-binding fibroblasts isolated from healthy donors, or from ChAc patients 
untreated, or treated with lithium (24 hours, 2mM) alone, or treated with Orai1 blocker 2-APB 
(24 hours, 50 µM) alone, or treated with both, lithium (2 mM) and 2-APB (50 µM) together for 
24 hours. All values were expressed in percent of the value in untreated fibroblasts isolated from 
ChAc patients. (g) Arithmetic means (±SEM, n=4-5 individuals) of the percentage of propidium 
iodide staining fibroblasts isolated from healthy donors, or from ChAc patients untreated, or treated 
with lithium (24 hours, 2mM) alone, or treated with Orai1 blocker 2-APB (24 hours, 50 µM) alone, 
or treated with both, lithium (2 mM) and 2-APB (50 µM) together for 24 hours. All values were 
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expressed in percent of the value in untreated fibroblasts isolated from ChAc patients. * p<0.05, 
*** p<0.001 indicates a statistically significant difference compared to the respective value in 
untreated ChAc fibroblasts. §§ p<0.01, §§§ p<0.001 indicates a statistically significant difference 
compared to the respective value in the absence of 2-APB. Figure adapted from (Pelzl et al., 2017a), 
changed. 
 
4.6 Orai1 and STIM1 transcript and protein levels in neurons 
differentiated from ChAc patients 
 
qRT-PCR was performed to quantify the mRNA expression of Orai1 and STIM1 in both 
healthy and ChAc iPSC-differentiated neurons, and the result showed that the transcript 
levels of Orai1 and STIM1 in ChAc neurons were significantly low compared with healthy 
neurons (Figure 10). 
 
Figure 10: Orai1 and STIM1 transcript levels comparison between iPSCs-differentiated 
neurons from healthy donors and ChAc patients 
Arithmetic means (±SEM, n=4) of (a) Orai1 and (b) STIM1 transcript levels in neurons isolated from 
healthy donors and ChAc patients. * p<0.05, ** p<0.01 indicates a statistically significant difference 
compared to the respective value in iPSC-differentiated neurons from healthy donors. Figure adapted 
from (Pelzl et al., 2017b), changed. 
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The difference in transcript levels reflected on protein abundance and made it in iPSC-
differentiated neurons from ChAc patients significantly lower than those from healthy donors 
(Figure 11). 
 
Figure 11: Orai1 and STIM1 protein abundance in iPSC-differentiated neurons from healthy 
donors and ChAc patients. 
Original western blot of (a) Orai1 and (c) STIM1 protein abundance in iPSCs-differentiated neurons 
from healthy donors (Healthy) compared with neurons differentiated from ChAc patients (ChAc). 
(b) Arithmetic means (±SEM, n=4) of Orai1 protein levels in neurons isolated from healthy donors 
and ChAc patients. (d) Arithmetic means (±SEM, n=3) of STIM1 protein levels in neurons 
differentiated from healthy donors and ChAc patients.  
** p<0.01, *** p<0.001 indicates a statistically significant difference compared to the respective 
value in iPSC-differentiated neurons from healthy donors. Figure adapted from (Pelzl et al., 2017b), 
changed. 
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4.7 Lithium treatment upregulates Orai1 and STIM1 mRNA expression 
and protein abundance in iPSC-differentiated ChAc neurons 
 
To check the effect of lithium treatment on the transcript levels in iPSCs-differentiated ChAc 
neurons, neurons were treated with lithium (2 mM) for 24 hours and then qRT-PCR was 
applied (see 3.3). The results showed a significant increase in the transcript levels of Orai1 
and STIM1 in lithium-treated neurons than untreated ones (Figure 12). To study the possible 
pathway of the effect that lithium does on the transcription of Orai1 and STIM1, the role of 
the serum & glucocorticoid-inducible kinase (SGK1) was checked as it regulates the 
transcription of Orai1 and STIM1 (Eylenstein et al., 2011). For this purpose, neurons were 
treated additionally with (10 µM) GSK650394, SGK1 inhibitor, which reversed the effect of 
lithium. The transcript levels of Orai1 and STIM1 were in neurons treated with lithium and 
GSK650394 together significantly lower than lithium just treated neurons, and even lower 
than untreated ChAc neurons (Figure 12). 
 
Figure 12: Transcription levels of Orai1 and STIM1 after lithium treatment with and without 
SGK1 inhibitor GSK650394 in iPSC-differentiated neurons from ChAc patients. 
Arithmetic means of (a) Orai1 and (b) STIM1 mRNA abundance in untreated (Ø) iPSCs-
differentiated ChAc neurons and after 24 h of lithium (2 mM) treatment without (Li+) and with 
(Li++GSK) presence of SGK1 inhibitor GSK650394 (10 µM). ## p<0.01, ### p<0.001 indicates 
statistically significant difference compared to untreated neurons. §§ p<0.01, §§§p<0.001 indicates a 
statistically significant difference compared to the respective value of lithium alone treated neurons. 
Figure adapted from (Pelzl et al., 2017b), changed. 
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Western blotting was used to check if the effect of lithium treatment was the same on protein 
abundance as mRNA abundance. 
Again, neurons were treated with (2 mM) lithium for 24 hours and that resulted in a 
significant increase of Orai1 and STIM1 protein abundance (Figure 13). Additional treatment 
with (10 µM) of SGK1 inhibitor GSK650394 reversed the effect of lithium and decreased the 
levels of Orai1 and STIM1 protein abundance (Figure 13). 
 
Figure 13: Protein abundance of Orai1 and STIM1 after lithium treatment without and with 
SGK1 inhibitor GSK650394 in iPSC-differentiated neurons from ChAc patients. 
Original western blot of (a) Orai1 and (c) STIM1 protein abundance in untreated iPSCs-differentiated 
ChAc neurons (Ø) compared with neurons after (2 mM) lithium treatment for 24 hours without (+Li) 
and with (+Li+GSK) presence of (10 µM) SGK1 inhibitor GSK650394. (b) Arithmetic means 
(±SEM, n=4) of Orai1 protein levels in iPSCs-differentiated ChAc neurons without and with (2 mM) 
lithium treatment for 24 hours without or with addition of (10 µM) SGK1 inhibitor GSK650394. 
(d) Arithmetic means (±SEM, n=3) of STIM1 protein levels in iPSCs-generated ChAc neurons 
without and with (2 mM) lithium treatment for 24 hours without or with addition of (10 µM) SGK1 
inhibitor GSK650394. # p<0.05, ## p<0.01 indicates statistically significant to respective value in 
untreated samples. § p<0.05, §§ p<0.01 indicates statistically significant to respective value in lithium 
alone treatment. Figure adapted from (Pelzl et al., 2017b), changed. 
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4.8 Lithium treatment up-regulates SOCE in iPSC-differentiated ChAc 
neurons 
To check if the decreased expression of Orai1 and STIM1 in ChAc generated neurons is 
paralleled by impairment of store-operated Ca2+ entry (SOCE), the calcium measurement 
method was processed using Fura2 fluorescence (see 3.5). Starting is cells exposure to the 
sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor thapsigargin (1 µM) in the 
absence of extracellular Ca2+, which empties the intracellular Ca2+ stores and causes an 
increase of [Ca2+]i in healthy neurons similar to ChAc neurons (Figure 14 a-c). Then 
subsequent extracellular Ca2+ was added again in the presence of thapsigargin which caused a 
sharp increase of [Ca2+]i referring to SOCE, and this effect was in ChAc neurons significantly 
less than healthy neurons, and this effect was significant in both the slope and the peak of 
[Ca2+]i (Figure 14 a,d,e). 
SOCE was measured also after treatment with (2 mM) lithium for 24 hours to check if this 
has an effect, and it resulted in a significant increase of both peak and slope of SOCE in 
lithium-treated samples in comparison to untreated ChAc neurons and resulted that SOCE in 
ChAc neurons treated with lithium was similar to untreated healthy neurons (Figure 14 d,e). 
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Figure 14: Effect of lithium treatment on intracellular Ca2+ release and SOCE in neurons 
differentiated from healthy donors and ChAc patients. 
(a) Representative tracings of Fura-2 fluorescence-ratio in fluorescence spectrometry before and after 
extracellular Ca2+ removal (0 Ca2+) and in the presence of thapsigargin (1 µM) and then re-addition of 
extracellular Ca2+ in iPSCs- differentiated neurons from healthy donors and from ChAc patients 
without and with (24 hours, 2 mM) lithium treatment. (b,c) Arithmetic means (±SEM, n=37-74 cells 
from 4 individuals) of peak (b) and slope (c) increase of Fura-2-fluorescence-ratio after addition of 
thapsigargin (1 µM) in iPSCs-differentiated neurons from healthy donors and in iPSCs- differentiated 
neurons from ChAc patients without and with lithium (24 hours, 2 mM) treatment. (d,e) Arithmetic 
means (±SEM, n=37-74 cells from 4 individuals) of peak (d) and slope (e) increase of Fura-2-
fluorescence-ratio which follows the re-addition of extracellular Ca2+ in iPSC-generated neurons from 
healthy donors and in iPSCs-differentiated neurons from ChAc patients without and with lithium 
(24 hours, 2 mM) treatment. * p<0.05 indicates a statistically significant difference compared to 
respective value in neurons from healthy donors, # p<0.05 indicates a statistically significant 
difference compared to respective value in neurons from ChAc patients untreated with lithium. Figure 
adapted from (Pelzl et al., 2017b), changed. 
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4.9 Lithium supports the survival of ChAc iPSC-differentiated neurons 
 
To check if the difference that was found in SOCE between healthy and ChAc neurons is 
paralleled with a difference in neuronal apoptosis, annexin-V binding and propidium iodide 
uptake were measured to identify the apoptotic neurons by flow cytometry (see 3.6). The 
results showed that the percentage of annexin-V-binding and propidium iodide uptake in 
iPSCs-differentiated neurons from ChAc patients was significantly higher than in iPSCs-
differentiated neurons from healthy donors (Figure 15 a,b,f,g). Treatment with 2 µM lithium 
for 24 hours changed the results and showed that the percentage of annexin-V-binding and 
propidium iodide uptake in treated ChAc neurons was significantly lower than the percentage 
in untreated ChAc neurons (Figure 15 b,c,f,g). To check if the effect of lithium treatment on 
Orai1 has a further effect on apoptosis, ChAc neurons were treated with Orai1 blocker 2-APB 
(50 µM) with and without the addition of (2 mM) lithium. This exposure resulted in a 
significant increase in the percentage of annexin-V-binding and propidium iodide uptake and 
reversed the effect of lithium treatment on this percentage in ChAc neurons (Figure 15 
d,e,f,g). 
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Figure 15: Effect of lithium and Orai1 blocking on phosphatidylserine translocation and 
propidium iodide uptake in iPSC-differentiated neurons from healthy donors and ChAc 
patients. 
(a,e) Representative dot blots of annexin-V-binding versus propidium iodide staining in 
iPSCs-differentiated neurons from healthy donors and from ChAc patients without and with treatment 
with lithium (24 hours, 2 mM), and with 2-APB (50 µM) alone or with lithium treatment (2 mM) 
together. (f,g) Arithmetic means (±SEM, n=4-5 individuals) of normalized annexin-V-binding (f) or 
propidium iodide (g) stained iPSCs-differentiated neurons from healthy donors, ChAc patients 
without and with lithium (24 hours, 2 mM) treatment, with Orai1 blocker 2-APB (50 µM) alone or 
with lithium together. ** p<0.01 indicates a statistically significant difference compared to the 
respective value in neurons from healthy donors. ## p<0.01 indicates a statistically significant 
difference compared to the respective value in ChAc neurons without treatment. § p<0.05, §§ p<0.01 
indicates a statistically significant difference compared to the respective value in ChAc neurons 
without 2-APB treatment. Figure adapted from (Pelzl et al., 2017b). 
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4.10 Inhibition of NFкB abrogates the effect of lithium on Orai1 and 
STIM1 mRNA and protein abundance in iPSC-differentiated ChAc 
neurons 
To have a wider physiological insight of the pathway that makes lithium effective on the 
expression of Orai1 and STIM1, the role of NFкB, as a transcriptional activator of Orai1 and 
STIM1 (Eylenstein et al., 2012, Lang and Hoffmann, 2012), was checked. For this reason, 
iPSC-differentiated neurons from ChAc patients were treated with NFкB inhibitor wogonin. 
Wogonin is a known inhibitor of NFкB by inhibition of the phosphorylation of IкB and this 
prevents the translocation of NFкB into the nucleus (Zhao et al., 2010). To check if this is the 
effect also in ChAc neurons, we treated neurons with (50 µM) of NFкB inhibitor wogonin for 
24 hours. Neurons were then treated with both lithium (2 mM) and wogonin (50 µM) for 
24 hours. The results showed that wogonin alone treatment decreased significantly the 
transcript levels of Orai1 (Figure 16 a) and STIM1 (Figure 16 b). Treatment of neurons with 
lithium (24 hours, 2 mM) together with NFкB inhibitor wogonin (50 µM) resulted in 
abrogating the effect of lithium and a significant decrease in Orai1 and STIM1 transcript 
levels compared even with untreated ChAc neurons (Figure 16). 
 
Figure 16: Effect of lithium treatment with and without NFкB inhibition by wogonin on Orai1 
and STIM1 transcript levels in ChAc neurons. 
Arithmetic means of (a) Orai1 and (b) STIM1 transcript levels in iPSCs-differentiated neurons from 
ChAc patients untreated, treated with lithium (24 hours, 2 mM) alone, treated with NFкB inhibitor 
wogonin (24 hours, 50 µM) alone or treatment with both lithium (2 mM) and wogonin (50 µM) for 
24 hours. ## p<0.01, ### p<0.001 indicates statistically significant difference compared to respective 
value in untreated ChAc neurons. §§ p<0.01, §§§ p<0.001 indicates a statistically significant 
difference compared to the respective value in ChAc neurons treated with lithium alone. Figure 
adapted from (Sukkar et al., 2018), changed. 
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To check if the effect of NFкB inhibition with wogonin on the transcript levels of Orai1 and 
STIM1 is paralleled with the same effect on protein abundance, iPSC-differentiated neurons 
from ChAc patients were treated with lithium (2 mM) with and without wogonin (50 µM). 
Then western blotting was employed to check the protein abundance (see 3.4). The results 
showed that treatment with NFкB inhibitor wogonin (50 µM) together with lithium (2 mM), 
abrogated the effect of lithium and led to a significant decrease in the protein abundance 
Orai1 and STIM1 comparing to treatment with lithium (2 mM) alone (Figure 17). 
 
Figure 17: Influence of NFкB inhibitor wogonin on lithium treatment on the protein abundance 
of Orai1 and STIM1. 
 (a,b) Original western blot of Orai1 (a) and STIM1(b) protein abundance in iPSCs-differentiated 
ChAc neurons untreated or with lithium (24 hours,2 mM) treatment alone or together with NFкB 
inhibitor wogonin (50 µM). (c,d) Arithmetic means (±SEM, n=5) of Orai1 (c) and STIM1 (d) protein 
abundance in iPSCs-generated neurons from ChAc patients untreated, treated with lithium (24 hours, 
2 mM) or treated with both lithium (2 mM) and NFкB inhibitor wogonin (50 µM) for 24 hours. 
# p<0.05, ## p<0.01 indicates statistically significant difference compared to respective value in 
untreated ChAc neurons. § p<0.05, §§§ p<0.001 indicates a statistically significant difference 
compared to the respective value in ChAc neurons treated with lithium alone. Figure adapted from 
(Sukkar et al., 2018), changed. 
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4.11 Inhibition of NFкB abrogates the effect of lithium treatment on 
SOCE in iPSC-differentiated ChAc neurons 
 
Fura-2 fluorescence was employed to check if the altered expression of Orai1 and STIM1 is 
also paralleled by changes in store-operated Ca2+ entry (SOCE) (see 3.5). After emptying the 
intracellular Ca2+ stores, a transient increase in [Ca2+]i happened and this increase was in 
samples treated with lithium alone higher than those untreated ChAc neurons (Figure 18). 
Re-addition of extracellular Ca2+ in the presence of thapsigargin resulted in an increase of 
[Ca2+]i significantly higher in samples treated with lithium (2mM) alone compared to 
untreated samples (Figure 18 d,e). SOCE was significantly decreased in ChAc neurons 
treated with NFкB inhibitor wogonin (50 µM) compared with untreated ChAc neurons and 
also with when lithium treatment was given with wogonin (Figure 18 d,e). 
 57 
 
 Results 
 
 
Figure 18: Intracellular Ca2+ release and store-operated Ca2+ entry (SOCE) after treatment with 
lithium without or with NFкB inhibitor wogonin in iPSC-differentiated neurons from ChAc 
patients. 
(a) Representative tracings of Fura-2 fluorescence-ratio in fluorescence spectrometry before and 
following extracellular Ca2+ removal (0 Ca2+) and then the addition of SERCA inhibitor thapsigargin 
(1 µM), followed by re-addition of extracellular Ca2+ in neurons generated from ChAc patients 
untreated and treated with lithium (24 hours, 2 mM) alone, with NFкB inhibitor wogonin 
(24  hours, 50 µM) alone, or both lithium and wogonin treatment. (b,c) Arithmetic means (±SEM, 
n=30-40 cells from 3 individuals) of (b) slope and (c) peak increase of Fura-2 fluorescence-ratio after 
the addition of (1 µM) thapsigargin in neurons generated from ChAc patients untreated and treated 
with lithium (24 hours, 2 mM) alone, with NFкB inhibitor wogonin (24 hours, 50 µM) alone, or both 
lithium and wogonin treatment. (d,e) Arithmetic means of (d) slope and (e) peak increase of Fura-2 
fluorescence-ratio after re-addition of extracellular Ca2+ indicating SOCE in neurons generated from 
ChAc patients untreated and treated with lithium (24 hours, 2 mM) alone, with NFкB inhibitor 
wogonin (24 hours, 50 µM) alone, or both lithium and wogonin treatment. # p<0.05, ## p<0.01 
indicates statistically significant difference compared to respective value in untreated ChAc neurons. 
§§ p<0.01 indicates a statistically significant difference to the respective value in ChAc neurons 
treated with lithium alone. Figure adapted from (Sukkar et al., 2018), changed. 
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4.12 Wogonin abrogates the effect of lithium on the survival of iPSC-
differentiated neurons from ChAc patients 
To explore if the inhibition of NFкB will influence the effect of lithium on the survival of 
ChAc neurons, again phosphatidylserine translocation utilizing annexin-V-binding and 
propidium iodide uptake was measured (see 3.6). The results showed that NFкB inhibitor 
wogonin treatment (50 µM) abrogated and reversed the effect of lithium when treated 
together and decreased both the annexin V binding percentage and propidium iodide uptake 
(Figure 21). 
 
Figure 19: Influence of wogonin on the lithium effect on survival of iPSC-differentiated neurons 
from ChAc patients.  
(a-d) Representative dot blots of annexin-V-binding versus propidium iodide staining in 
iPSCs-generated neurons from ChAc patients without and with treatment with lithium (24 hours, 2 
mM), and with NFкB inhibitor wogonin (50 µM) alone or with lithium treatment (2 mM) together.  
(e,f) Arithmetic means (±SEM, n=3 individuals) of normalized annexin-V-binding (e) or propidium 
iodide (f) stained iPSCs-generated neurons from ChAc patients without and with lithium (24 hours, 2 
mM) treatment, with NFкB inhibitor wogonin (50 µM) alone or with lithium together. # p<0.05, ## 
p<0.01, ### p<0.001 indicates a statistically significant difference compared to the respective value in 
untreated ChAc neurons.  
§§§ p<0.001 indicates a statistically significant difference compared to the respective value in neurons 
treated with lithium alone.  
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5. Discussion  
 
This study is done to gain a pathophysiological insight into the effect of 
Chorea Acanthocytosis (ChAc), i.e. chorein deficiency, on cell survival and defective 
regulation of Orai1 and STIM1 expression with subsequent impairment of store-operated 
Ca2+ entry (SOCE). SOCE is responsible to trigger oscillations of cytosolic Ca2+ activity 
([Ca2+]i) and thus affects cell survival and growth (Taylor et al., 2008, Heise et al., 2010, 
Parkash and Asotra, 2010). These oscillations appear when the increase of intracellular Ca2+ 
concentration occurs as repetitive short pulses, which has a role in the activation of Ca2+-
dependent transcription factors and the reorganization of actin filament network (Lang et al., 
2006b, Lang and Stournaras, 2014), but when the increase of cytosolic Ca2+ activity is 
sustained, it leads to apoptosis in a variety of cell types (Green and Reed, 1998, Berridge et 
al., 2000, Lang and Hoffmann, 2012).  
In this study, it is shown that SOCE was significantly down-regulated in fibroblasts and 
iPSC-differentiated neurons of ChAc patients compared with samples from healthy donors 
(Pelzl et al., 2017a, Pelzl et al., 2017b). The decrease of SOCE was synchronized by 
increased levels of apoptosis in ChAc fibroblasts and iPSC-differentiated neurons (Pelzl et 
al., 2017a, Pelzl et al., 2017b). 
On the other hand, Orai isoforms and their regulators STIM 1 or 2 play a part in the Ca2+ 
oscillations and contribute to the survival and proliferation of tumor cells as well as neural 
stem/progenitor cells (Peinelt et al., 2006, Putney, 2007, Qu et al., 2011, Prevarskaya et al., 
2011, Bergmeier et al., 2013, Prevarskaya et al., 2014, Somasundaram et al., 2014). The 
protein and mRNA abundance of Orai1 and STIM1 were significantly downregulated in 
ChAc iPSC-differentiated neurons compared to healthy donors (Pelzl et al., 2017b). 
As ChAc disease has no clear cure so far (Velayos Baeza et al., 1993, Schneider et al., 2006), 
this study investigated the effect of the well-known psychiatric medicine, lithium, on the 
pathological variance in fibroblasts and iPSC-differentiated neurons of ChAc patients. 
Lithium proved a protective effect in this study by reducing apoptosis and upregulating 
SOCE in fibroblasts and iPSC-differentiated neurons from ChAc patients (Pelzl et al., 2017a, 
Pelzl et al., 2017b). 
The present study observes the signaling link between chorein deficiency and Orai1/STIM1. 
Accordingly, Orai1 and STIM1 transcript and protein levels were elevated by lithium 
treatment in ChAc, while the protective effect of lithium was abrogated by Orai1 inhibition 
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(Pelzl et al., 2017a, Pelzl et al., 2017b, Sukkar et al., 2018). These observations could 
speculate that lithium may modify the pathophysiology of neurodegeneration in partly by up-
regulation of neuronal Orai1 and STIM1 expression as well as SOCE, which will lead to 
stimulate proliferation of neuronal progenitor cells and inhibit neuronal apoptosis 
(Somasundaram et al., 2014). 
Previously was shown that Orai1 expression is regulated by the PI3K pathway (Raimondi and 
Falasca, 2011). This pathway includes activation of serum and glucocorticoid-inducible 
kinase (SGK1), which in turn phosphorylates the IKK complex and thus activates it (Lang et 
al., 2006a). The active IKK phosphorylates IкB proteins that are bounded to NFкB, and when 
the latter is free, it migrates into the nucleus causing the transcriptional activation of Orai1 
and STIM1 and subsequently activating SOCE (Zhang et al., 2005a, Lang et al., 2012, 
Eylenstein et al., 2012) (Figure 20). Moreover, SGK1 is effective by the inhibition of 
Nedd4-2 induced degradation of Orai1 protein (Lang et al., 2012, Schmidt et al., 2014). 
Based on these observations, inhibition of SGK1 by GSK650394 in this study resulted in 
reversing the effect of lithium on SOCE and cell survival which highlights the impact of 
SGK1 on the protective role of lithium (Pelzl et al., 2017b). 
The mechanisms that reflect the neuroprotective effect of lithium are several. It activates Akt 
which in turn phosphorylates BAD protein resulting in suppressing cell death (Chalecka-
Franaszek and Chuang, 1999, Datta et al., 1997). Furthermore, lithium ions can also inhibit 
GSK-3 (Stambolic et al., 1996). This protective effect linking to many studies which showed 
that overexpression of GSK3-β caused apoptosis of neuronal PC12 cells (Pap and Cooper, 
1998), and GSK3, showed to elevate apoptosis of neuronal SH-SY5Y cells (Bijur et al., 
1999). In another study, cell death of sympathetic neurons that was mediated by loss of PI3K 
signaling was reduced by inhibition of GSK3 (Crowder and Freeman, 1998). These 
observations support the idea that GSK3 has a pro-apoptotic role in neuronal cells, and 
inhibition of GSK3 in these cells, which lithium does, improves the pro-survival PI3K 
signaling pathway (Maurer et al., 2014, Cross et al., 1995). 
Along these lines, NFкB could be also activated in two ways; either by Akt activation or by 
partial inactivation of GSK-3: on the one hand, when Akt is active, it leads to IKK 
stimulation which in turn phosphorylates the IкB protein and p65/RelA subunit to end with 
enhanced activation of NFкB (Bai et al., 2009). On the other hand, GSK3 can phosphorylate 
the NFкB inhibitory protein NFкB2/ p100 and thus prevents its IкB-like role in 
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suppressing NFкB, which enables NFкB to complete its pro-survival and transcriptional role 
(Siebenlist et al., 1994, Ghosh and Karin, 2002, Busino et al., 2012, Fukushima et al., 2012). 
Depending on these important observations, and as lithium is able to activate Akt and inhibit 
GSK3 as well, this could mean that the effect of lithium on the expression of Orai1 and 
STIM1 showed in this study, might be achieved through NFкB activation (Stambolic et al., 
1996, Chalecka-Franaszek and Chuang, 1999). 
As for experimental evidence, inhibition of NFкB by wogonin in this study decreased 
significantly Orai1 and STIM1 transcript levels as well as SOCE and induced apoptosis in 
fibroblasts and iPSC-differentiated neurons of ChAc patients (Sukkar et al., 2018). Moreover, 
it abrogated the stimulating effect of lithium, which reflects the stimulating effect of NFкB in 
neurons in both, the presence and absence of lithium, and highlights the potential role that 
NFкB may play in the effect of lithium (Sukkar et al., 2018). However, these observations are 
not evidencing whether NFкB has an inhibitory effect on neurodegeneration or not which is 
still to be investigated. 
This study does not address the signaling linking for cell apoptosis. It is more probable that 
this signaling will contain a role of the PI3K pathway, which includes the kinase SGK1 
(Raimondi and Falasca, 2011) and which are known for the upregulation of Orai1 (Lang et 
al., 2012). In view of the present study, the pathological suicidal death of neurons in ChAc 
patients, which is the decisive pathophysiological mechanism that leads to this devastating 
disease (Jung et al., 2011), could be delayed or even held by lithium treatment. 
A good and also critical feature of lithium ions is their water-solubility and the ability to 
distribute throughout all of the body water in the same way as sodium ions (Na+) (Sproule et 
al., 2000). Lithium can cross the blood-brain barrier (BBB) (Platman and Fieve, 1968). 
However, there are age-related changes in BBB as it becomes weaker by age which alters the 
uptake of lithium into the brain and thus affects the pharmacokinetics of lithium in the older 
adults (Mooradian, 1994, Sproule et al., 2000). Furthermore, the volume of distribution and 
renal clearance decreases with age also, and this emphasizes reducing the dose of lithium for 
older individuals (Hewick et al., 1977). Anyway, the onset age average of 
Chorea Acanthocytosis is 35 years old, which is early for the complications of lithium (Zhang 
et al., 2013). Studies showed neurotoxicity of lithium including prolonged recovery from 
lithium-induced delirium and adverse consequences on memory and speed of cognitive and 
psychomotor execution, but anyway, like the complications of weak BBB, these cases were 
 62 
 
 Discussion 
concerned in older individuals more compared with younger patients with bipolar disorder 
(Nambudiri et al., 1991, Pachet and Wisniewski, 2003, Zhang et al., 2013). 
Limitations of the study include the sensitivity of iPSC-differentiated neurons as they were 
transferred from the institute where they were generated to the further experiments institute, 
and they many times were not usable when they arrived, as well the lack number of patients 
with ChAc.  
 
 
Figure 20: Postulated regulation of PI3K pathway via chorein. 
Chorein interacts with PI3K and stimulates it (Wu et al., 2007, Foller et al., 2012, Honisch et al., 
2015c). Activation of PI3K leads to the formation of phosphatidylinositol 3,4,5-triphosphate (PIP3) 
from phosphatidylinositol 4,5-bisphosphate (PIP2) (Scharenberg and Kinet, 1998). 
3-phosphoinositide-dependent kinase (PDK1), which binds to PIP3, leads to phosphorylation and thus 
the activation of SGK1 (Lang and Cohen, 2001). In turn, SGK1 leads to phosphorylation of IкB and 
the translocation of NFкB into the nucleus where it works on the upregulation of Orai1 and STIM1 
(Lang et al., 2006a, Eylenstein et al., 2012). Accordingly, when chorein is nonfunctional, i.e. 
Chorea Acanthocytosis, this pathway will be inactive which leads to downregulation of Orai1 and 
STIM1 and thus SOCE, as well increases apoptosis levels (Velayos Baeza et al., 1993, Pelzl et al., 
2017a, Pelzl et al., 2017b, Sukkar et al., 2018, Foller et al., 2012, Honisch et al., 2015c).  
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6. Conclusion 
 
The present observations reveal that Chorea Acanthocytosis leads to the downregulation of 
Orai1 and STIM1 expressions, as well as store-operated Ca2+ entry which leads to 
compromising neuronal cell survival. On the contrary, lithium up-regulates store-operated 
Ca2+ entry and reduces neuronal apoptosis, beneficial effects abrogated by the pharmaceutical 
inhibitions of Orai1 or its regulators SGK1 and NFкB. 
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